The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.

@article{Norman1988TheUO,
  title={The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.},
  author={Douglas J. Norman and J. M. Barry and W. M. Bennett and Mario Leone and Karen R Henell and Barbara E. Funnell and Bruno Hubert},
  journal={American journal of kidney diseases : the official journal of the National Kidney Foundation},
  year={1988},
  volume={11 2},
  pages={90-3}
}
Thirty-one recipients of cadaver kidney transplants were given OKT3 monoclonal anti-T cell antibody for rejection treatment after conventional therapy had failed. Seventy-four percent of steroid or steroid and antithymocyte globulin (ATG) resistant rejections reversed with a standard course of OKT3. Rejections reversed in 85% of 26 patients treated within 90 days of transplantation. Late rejections treated more than 90 days after transplantation were poorly responsive to OKT3 and graft survival… CONTINUE READING